Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Clover Biopharmaceuticals's Enterprise Value is HK$2,671.30 Mil.
Clover Biopharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-213.91 Mil. Therefore, Clover Biopharmaceuticals's EV-to-FCF for today is -12.49.
The historical rank and industry rank for Clover Biopharmaceuticals's EV-to-FCF or its related term are showing as below:
HKSE:02197'
s EV-to-FCF Range Over the Past 10 Years
Min: -16.62 Med: -0.13 Max: 0.37
Current: -12.49
During the past 7 years, the highest EV-to-FCF of Clover Biopharmaceuticals was 0.37. The lowest was -16.62. And the median was -0.13.
HKSE:02197's EV-to-FCF is ranked worse than 100% of 332
companies
in the Biotechnology industry
Industry Median: 16.745
vs HKSE:02197: -12.49
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Clover Biopharmaceuticals's PE Ratio (TTM) for today is calculated as:
Clover Biopharmaceuticals's share price for today is HK$2.37.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Clover Biopharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.175.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Clover Biopharmaceuticals EV-to-FCF Related Terms
Clover Biopharmaceuticals EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02197 vs VRTX, REGN, RVMD: EV-to-FCF Comparison
For the Biotechnology subindustry, Clover Biopharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clover Biopharmaceuticals EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clover Biopharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Clover Biopharmaceuticals's EV-to-FCF falls into.
Clover Biopharmaceuticals's current Enterprise Value is HK$2,671.30 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Clover Biopharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-213.91 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clover Biopharmaceuticals (HKSE:02197) has a EV-to-FCF of -12.49 as of Aug. 14, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Clover Biopharmaceuticals and its competitors. According to the industry distribution chart, Clover Biopharmaceuticals ranks #999999 out of 332 companies in the Biotechnology industry.
Is Clover Biopharmaceuticals' EV-to-FCF too high?
Clover Biopharmaceuticals' current EV-to-FCF is -12.49. Based on the distribution chart, Clover Biopharmaceuticals ranks #999999 out of 332 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Clover Biopharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Clover Biopharmaceuticals' EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clover Biopharmaceuticals ranks #999999 out of 332 companies for EV-to-FCF. This places Clover Biopharmaceuticals in the lower half of its industry. The industry median EV-to-FCF is 16.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.75, based on 332 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Clover Biopharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clover Biopharmaceuticals's current EV-to-FCF is -12.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clover Biopharmaceuticals stock overvalued right now?
Clover Biopharmaceuticals (HKSE:02197) has a current EV-to-FCF of -12.49. The current EV-to-FCF is -12.49. Clover Biopharmaceuticals' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Clover Biopharmaceuticals (HKSE:02197), the current EV-to-FCF is -12.49 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Clover Biopharmaceuticals Ltd is a clinical-stage biotechnology company committed to unleashing the power of vaccines to save lives and improve health around the world. The leverage the proprietary Trimer-Tag technology platform to conduct R&D for vaccines that can fulfill unmet needs, with a focus on building a respiratory vaccine franchise to reduce the burden of vaccine-preventable diseases. The Group has only one operating segment, which is the research and development, manufacturing, and commercialisation of vaccines. Geographically, the company earns revenue from Mainland China and Korea.
28GF Score
Get the complete analysis for HKSE:02197
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02197 has been successfully added to your 
